07:00 , Apr 5, 2010 |  BC Week In Review  |  Clinical News

Asclera regulatory update

FDA approved an NDA from Chemische for Asclera polidocanol to treat varicose veins, including spider and reticular veins. BioForm Medical Inc. (San Mateo, Calif.) has exclusive U.S. and Canadian rights to commercialize the injectable sclerosing...
07:00 , Mar 29, 2010 |  BC Week In Review  |  Clinical News

Radiesse dermal filler regulatory update

BioForm Medical Inc. , San Mateo, Calif.   Product: Radiesse dermal filler   Business: Endocrine   The Centers for Medicare & Medicaid Services (CMS) issued a policy decision to allow reimbursement for dermal fillers to...
07:00 , Mar 29, 2010 |  BC Week In Review  |  Clinical News

Sculptra injectable poly-L-lactic acid regulatory update

sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France   Product: Sculptra injectable poly-L-lactic acid   Business: Endocrine   The Centers for Medicare & Medicaid Services (CMS) issued a policy decision to allow reimbursement for dermal fillers to...
08:00 , Jan 25, 2010 |  BC Week In Review  |  Company News

BioForm, Merz deal

Merz began its previously announced tender offer to acquire all outstanding shares of BioForm for $5.45 per share. The tender offer expires at midnight on Feb. 12 (see BioCentury, Jan. 11). BioForm Medical Inc. (NASDAQ:BFRM),...
08:00 , Jan 11, 2010 |  BC Week In Review  |  Company News

BioForm, Merz deal

Merz will acquire dermatology company BioForm Medical for $5.45 per share, or about $253 million. The price is a 60% premium to BioForm's close of $3.40 on Dec. 31, 2009, the last trading day before...
08:00 , Jan 11, 2010 |  BioCentury  |  Finance

Regulatory milestones

Actelion Ltd. (SIX:ATLN) gained CHF1.70 to CHF56.90 last week after FDA posted briefing documents ahead of Tuesday's meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to discuss an sNDA for Zavesca miglustat to treat...
01:27 , Jan 5, 2010 |  BC Extra  |  Company News

Merz to acquire BioForm

Merz GmbH & Co. KGaA (Frankfurt, Germany) will acquire dermatology company BioForm Medical Inc. (NASDAQ:BFRM) for $5.45 per share, or about $253 million. The price is a 61% premium to BioForm's close of $3.40 on...
07:00 , Sep 8, 2008 |  BC Week In Review  |  Clinical News

Aethoxysklerol polidocanol: Phase III data

Data from the German Phase III EASI trial in 338 patients with C1 varicose veins, showed that polidocanol met the primary endpoint of a significant treatment success vs. placebo (96% vs. 8% at week 12...